IL17A and rheumatoid arthritis: Detailed knowledge of IL-17A biology in humans has led to the targeted development of immunotherapeutic monoclonal antibodies (mabs) to block IL-17A and the IL-17RA receptor for the treatment and control of psoriasis, multiple sclerosis and rheumatoid arthritis [4].